Using PET/MR imaging for NK/T-cell lymphoma evaluation
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma: a Prospective, Single-arm Clinical Study
This study is testing if a new type of imaging that combines PET and MRI can help doctors better understand and treat patients with newly diagnosed NK/T-cell lymphoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 14 Years to 70 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT05662540 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Positron Emission Tomography/Magnetic Resonance (PET/MR) imaging in staging and assessing the treatment efficacy of newly diagnosed NK/T-cell lymphoma. The goal is to develop a more accurate prognostic system that can guide treatment decisions for patients with this aggressive lymphoma subtype. By integrating PET and MR imaging, the study aims to overcome the limitations of current diagnostic methods that require separate examinations, which can be inconvenient for patients.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 14 to 70 with a pathologically diagnosed NK/T-cell lymphoma who have not received prior treatment.
Not a fit: Patients with aggressive NK cell leukemia, severe organ insufficiency, or those with contraindications for PET/MR imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved staging accuracy and treatment guidance for patients with NK/T-cell lymphoma.
How similar studies have performed: While PET/CT and MR imaging have been used separately in similar contexts, this integrated approach is relatively novel and has not been extensively tested in this specific lymphoma subtype.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016 * Age from 14 to 70 years-old * ECOG 0-2 score * Patients with a life expectancy of at least 6 months * Patient has not been treated before for NK/T cell lymphoma * Commit to abide by the research procedures and cooperate with the implementation of the whole process of research * Written informed consent Exclusion Criteria: \- Subjects who meet any of the following criteria are not eligible for study entry * Diagnosed aggressive NK cell leukemia * Pregnant or lactating women * Liver and kidney insufficiency * Other PET/MR contraindications: 1. Those with implanted functional electronic devices such as cardiac pacemakers 2. Carotid aneurysm clipping and other implants are ferromagnetic materials 3. Implanted perfusion devices such as insulin perfusion pumps 4. Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients 5. Those who are claustrophobic * Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Weili Zhao
- Email: zwl_trial@163.com
- Phone: +862164370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.